SEC Form 4 · accession 0001567619-18-002681
ADURO BIOTECH, INC. · ADRO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Natalie Sacks
Officer — Chief Medical Officer
Period of report
Sep 12, 2018
Accepted (ET)
Sep 14, 2018 · 7:25 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001435049
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Sep 12, 2018 | A | 87,200 | $0.00 | A | 176,748 | D | |
| Common StockF3 | Sep 13, 2018 | S | 3,028 | $6.4993 | D | 173,720 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents grant of restricted stock units payable in common stock that vest in four equal annual installments from the grant date of September 12, 2018.
- F2The shares were sold to cover the tax obligation that occurred upon the vesting of an RSU.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.25 to $6.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.